Evaluation of the vital staining method for Lacazia loboi through the experimental inoculation of BALB/c mice.

The viability of the currently unculturable fungal pathogen Lacazia loboi can be determined by means of fluorescein diacetate-ethidium bromide (FD-EB) staining. This technique can be used in experimental study of the mycosis, in attempts to cultivate the fungus and in attempts to gauge the success of therapies. In the present study, the potential applications of FD-EB vital staining were studied using a proposed murine experimental model of lobomycosis. BALB/c mice were inoculated in the footpads with an L. loboi suspension that appeared in FD-EB staining to have lost viability after being held for 15 days at room temperature, whereas a control group of mice was inoculated with apparently viable fungi. The animals were killed after 1, 2, 4, 6, 8, 11 and 13 months. Both inoculated footpads were excised, one for determination of viability and the other for histological examination. In the group injected with nonviable material, no active infection was noted; inoculation sites showed small quantities of macrophage-laden infiltrate and no viable fungal cells. In the control group, the infection progressed with exuberant infiltrates surrounding copious fungal growth, most of which consisted of cells staining as viable in FD-EB. These results suggest that the FD-EB vital staining is a sensitive and specific method that can reliably be used for viability determination in L. loboi.     

Lipid profile in haemodialysis patients treated with recombinant human erythropoietin

Background: The long-term effect of recombinant human erythropoietin (rhEPO) on the blood-lipid profile has not been well documented. The aim of this study was to evaluate whether rhEPO therapy affects the lipid pattern. Methods: A group of 102 maintenance haemodialysis patients were treated for 2 years with rhEPO given intravenously at the end of the dialysis session. Attempts were made to keep the haemoglobin (Hb) at 10-11 g/dl and/or the haematocrit (Hct) at 30-35%. Twenty maintenance haemodialysis patients not treated with rhEPO were examined as controls. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteins A1 and B, and lipoprotein (a) [Lp (a)] were assessed at baseline (without rhEPO), and 1 and 2 years after the beginning of treatment. Hb, Hct and ferritin were measured monthly, and Kt/v was evaluated monthly and kept above 1.1. Results: During follow-up, in both groups, there was a significant increase in Apo A1 and no significant changes in the other lipid parameters. In the treated group, Hb and Hct increased significantly after the fourth month of treatment. Conclusions: Erythropoietin therapy does not affect significantly the levels of total cholesterol, LDL- and HDL-cholesterol, triglycerides, Apo B and Lp (a) in maintenance hemodialysis patients.     

Indications and limitations of echocardiography in evaluating aortic valve insufficiency

Echocardiography (Echo) is the best non-invasive technique to study aortic regurgitation (AR). The authors (AA) start reviewing the place of M-Mode (MM) and two-dimensional (2D) Echo on the identification of AR and its cause, as well as on the assessment of left ventricular function. Secondly, the AA study the role of Doppler (Dp) techniques--pulsed (PDp), continuous (CDp) and colour coded (CCDp)--analysing their relative advantages and complementarity. They conclude that AR is best identified by PDp and MM Echo, its cause may be recognized by MM and 2D Echo, and its importance is correctly judged by CDp and CCDp Echo. Left ventricular function is best appreciated by 2D Echo, helped by CDp and CCDp Echo. The AA also state that, in AR, an haemodynamic study is injustifiable, unless Echo is technically incomplete, there is pluri-valvular disease insufficiently clarified, or coronarography is necessary.